TTY Biopharm Company Limited

TPEX:4105 Stock Report

Market Cap: NT$18.3b

TTY Biopharm Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for TTY Biopharm.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth15.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated04 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Apr 02

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Mar 15

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Today we will run through one way of estimating the intrinsic value of TTY Biopharm Company Limited ( GTSM:4105 ) by...
Analysis Article • Feb 25

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Could TTY Biopharm Company Limited ( GTSM:4105 ) be an attractive dividend share to own for the long haul? Investors...
Analysis Article • Feb 07

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

With its stock down 11% over the past three months, it is easy to disregard TTY Biopharm (GTSM:4105). However, stock...
Analysis Article • Jan 19

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

The latest analyst coverage could presage a bad day for TTY Biopharm Company Limited ( GTSM:4105 ), with the analysts...
Analysis Article • Jan 10

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...
Analysis Article • Dec 15

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Nov 25

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Dividend paying stocks like TTY Biopharm Company Limited (GTSM:4105) tend to be popular with investors, and for good...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TTY Biopharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:4105 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20267,046N/AN/AN/A1
3/31/20266,5151,6111,7812,019N/A
12/31/20256,4531,5591,6111,762N/A
9/30/20256,5031,7901,6101,784N/A
6/30/20256,2161,5831,4101,564N/A
3/31/20256,0791,5601,2441,396N/A
12/31/20245,8941,4501,2151,349N/A
9/30/20245,8261,1201,0171,122N/A
6/30/20245,7261,1249821,087N/A
3/31/20245,6131,1711,0991,211N/A
12/31/20235,5061,1299861,085N/A
9/30/20235,3941,168758891N/A
6/30/20235,2871,1301,0911,219N/A
3/31/20235,1911,1061,0211,142N/A
12/31/20225,0621,0941,1001,236N/A
9/30/20224,9971,1931,2941,399N/A
6/30/20224,7311,1091,0151,116N/A
3/31/20224,6098561,1561,247N/A
12/31/20214,5368321,1821,256N/A
9/30/20214,270751873937N/A
6/30/20214,235720768937N/A
3/31/20214,092874444619N/A
12/31/20204,222924344526N/A
9/30/20204,130693455646N/A
6/30/20204,255787894980N/A
3/31/20204,4458601,1231,191N/A
12/31/20194,466900N/A1,210N/A
9/30/20194,4471,236N/A1,298N/A
6/30/20194,2041,263N/A980N/A
3/31/20194,1101,499N/A893N/A
12/31/20184,0361,461N/A1,074N/A
9/30/20184,1021,696N/A1,013N/A
6/30/20184,2401,631N/A1,099N/A
3/31/20184,1731,379N/A1,237N/A
12/31/20174,0791,345N/A997N/A
9/30/20173,8741,088N/A980N/A
6/30/20173,7651,023N/A1,031N/A
3/31/20173,7951,134N/A1,109N/A
12/31/20163,7611,193N/A1,227N/A
9/30/20163,7331,536N/A1,083N/A
6/30/20163,6121,565N/A938N/A
3/31/20163,3891,393N/A947N/A
12/31/20153,1951,211N/A639N/A
9/30/20153,0581,133N/A698N/A
6/30/20152,929986N/A725N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4105's forecast earnings growth is above the savings rate (1.3%).

Earnings vs Market: Insufficient data to determine if 4105's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4105's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4105's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4105's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4105's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/16 23:04
End of Day Share Price 2026/06/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TTY Biopharm Company Limited is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christine WangDaiwa Securities Co. Ltd.
Caren HuangJ.P. Morgan
Yu-Ying YangKGI Securities Co. Ltd.